Free Trial

These 5 growth stocks are now in buy ranges

growth stocks

Key Points

  • With the recent uptrend in the S&P 500, several stocks with top revenue and earnings growth rates are actionable.
  • Sales and earnings growth can tell you which stocks could be winners, while the chart shows the time to buy.
  • Stocks from the infotech and biotech sectors are among the market's best growth performers.
  • 5 stocks we like better than ANSYS

Chart patterns and consolidations are worth watching, as they provide actionable guidance for making a purchase. 

With the recent uptrend in large-cap stocks, as reflected by the performance of the SPDR S&P 500 ETF Trust NYSEARCA: SPY, many stocks with top revenue and earnings growth rates are flashing bullish technical signals. 

Large caps with strong chart action include Affirm Holdings Inc. NASDAQ: AFRM, MongoDB Inc. NASDAQ: MDB, UiPath Inc. NYSE: PATH, Synopsys Inc. NASDAQ: SNPS and Crispr Therapeutics AG NASDAQ: CRSP.

Given the continued outperformance of growth stocks in recent months, it shouldn’t come as a surprise that all those stocks are categorized as technology stocks or biotech stocks. The tech and biotech industries are known for innovation and a fast pace of disruption. 

Growth stocks good candidates for chart analysis

Technical analysis often aligns better with growth stocks due to their price momentum. Growth stocks exhibit stronger trends and tend to see more significant price movements, making trend indicators more valuable. 

In contrast, value and dividend stocks, known for stability and steady income, may not display the same level of price fluctuations, making technical analysis less effective.

In those cases, tracking dividend yields and fundamental metrics, such as revenue and earnings increases, may be all you need to make investing decisions. 

Affirm gapping higher 

Shares of the buy now, pay later company gapped up 5.16% on January 22. Despite some selling since then, the stock continues to hold above its 50-day moving average, as you can see on the Affirm chart

The stock is currently in actionable range, as it is trading between its 50-day line and its previous high of $52.48, from December 7. 

Wall Street expects Affirm to become profitable this year for the first time, with earnings doubling to 65 cents a share next year. 

MongoDB forming bullish consolidation

The MondoDB chart shows the stock forming a base after a cup-with-handle breakout failed in early December. In the past month, upside weeks have shown higher trading volume than downside weeks, a bullish sign. 

The database platform maker began reversing a downtrend in early January, is currently trading above its 50-day moving average, offering an early entry point before the stock clears its December 4 high of $442.84. 

Analysts are forecasting explosive earnings growth this year of 258%, to $2.90 per share. The rapid pace of data migration to the cloud is a growth accelerant. 

AI powering UIPath higher

UIPath, which develops AI-powered business automation software, is forming a base with support above its 50-day average after gapping 27% higher in early December following its quarterly report. 

The UIPath chart shows the stock consolidating below a December 19 high of $26.52. Watch for it to clear that price in heavy volume, to show upside momentum. However, more aggressive investors could use continued support above the 50-day line as an early buy point. 

Synopsys’ Ansys deal to boost shareholder value

Synopsys stock has been a stellar performer within the Technology Select Sector SPDR Fund NYSEARCA: XLK, advancing 15.47% in the past three months and 54.72% in the past year. 

The chip design software maker is another company that’s been riding the wave of AI. A recent deal to acquire engineering simulation software company Ansys Inc. NASDAQ: ANSS is likely to offer further upside premium to shareholders. 

On the Synopsys chart, you’ll see the stock is forming a base. Synopsys stock regained its 50-day moving average on January 22. The stock is currently actionable below its prior high of $573.77.

Investors who hold on tight can see gains from Crispr

Crispr Therapeutics is a Swiss-American biotechnology company that develops gene-based treatments for serious diseases. As is common with biotechs, the stock is fairly volatile, with a beta of 1.96. The Crispr Therapeutics chart shows some wide intraday price swings.

That volatility can result in significant gains; Crispr stock is up 51.79% in the past three months, but investors had to stomach a rollercoaster ride to capture those gains. 

The stock’s current area of consolidation is sloppy, but aggressive investors could consider upside momentum during the week of January 22 as a catalyst for an early entry. 

Should you invest $1,000 in ANSYS right now?

Before you consider ANSYS, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANSYS wasn't on the list.

While ANSYS currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
3.688 of 5 stars
Synopsys (SNPS)
4.074 of 5 stars
Technology Select Sector SPDR Fund (XLK)N/A$214.35+1.2%0.60%36.81HoldN/A
MongoDB (MDB)
3.722 of 5 stars
$368.01-0.8%N/A-148.39Moderate Buy$444.57
Affirm (AFRM)
1.2154 of 5 stars
CRISPR Therapeutics (CRSP)
2.981 of 5 stars
UiPath (PATH)
3.7729 of 5 stars
$20.31-0.5%N/A-119.46Moderate Buy$27.41
Compare These Stocks  Add These Stocks to My Watchlist 

Kate Stalter

About Kate Stalter


Contributing Author

Retirement, Asset Allocation, and Tax Strategies


Kate Stalter has been a contributing writer for MarketBeat since 2021.

Additional Experience

Series 65-licensed investment advisor, financial advisor, Blue Marlin Advisors; investment columnist for Forbes, U.S. News & World Report

Areas of Expertise

Asset allocation, technical and fundamental analysis, retirement strategies, income generation, risk management, sector and industry analysis


Bachelor of Arts, Saint Mary’s College, Notre Dame, Indiana; Master of Business Adminstration, Kellogg School of Management at Northwestern University

Past Experience

Founder, financial advisor for Better Money Decisions; editor, stock trading instructor for Investor’s Business Daily; columnist, podcast host, video host for; contributor for Morningstar magazine

Featured Articles and Offers

Search Headlines: